Please wait while the formulary information is being retrieved.
Drug overview for VASOPRESSIN-0.9% NACL (vasopressin in 0.9 % sodium chloride):
Generic name: VASOPRESSIN IN 0.9 % SODIUM CHLORIDE
Drug class: Antidiuretic Hormone
Therapeutic class: Endocrine
Vasopressin (antidiuretic hormone) is a polypeptide hormone secreted by the neurons of the supraoptic and paraventricular nuclei of the hypothalamus and stored in the posterior pituitary (neurohypophysis) in mammals; the primary physiologic role of vasopressin is to maintain serum osmolality within a normal range, but the hormone also causes vasoconstriction.
No enhanced Uses information available for this drug.
Generic name: VASOPRESSIN IN 0.9 % SODIUM CHLORIDE
Drug class: Antidiuretic Hormone
Therapeutic class: Endocrine
Vasopressin (antidiuretic hormone) is a polypeptide hormone secreted by the neurons of the supraoptic and paraventricular nuclei of the hypothalamus and stored in the posterior pituitary (neurohypophysis) in mammals; the primary physiologic role of vasopressin is to maintain serum osmolality within a normal range, but the hormone also causes vasoconstriction.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for VASOPRESSIN-0.9% NACL (vasopressin in 0.9 % sodium chloride) have been approved by the FDA:
Indications:
None.
Professional Synonyms:
None.
Indications:
None.
Professional Synonyms:
None.
The following dosing information is available for VASOPRESSIN-0.9% NACL (vasopressin in 0.9 % sodium chloride):
Vasopressin dosage requirements are variable and must be adjusted according to patient response. In order to avoid adverse effects, it is desirable to give doses that are just sufficient to elicit the desired response.
There is limited information regarding exposure of vasopressin in patients with hepatic impairment and no specific dosage recommendations are available for such patients; dosage should be titrated to effect.
There is limited information regarding exposure of vasopressin in patients with renal impairment and no specific dosage recommendations are available for such patients; dosage should be titrated to effect.
There is limited information regarding exposure of vasopressin in patients with hepatic impairment and no specific dosage recommendations are available for such patients; dosage should be titrated to effect.
There is limited information regarding exposure of vasopressin in patients with renal impairment and no specific dosage recommendations are available for such patients; dosage should be titrated to effect.
Vasopressin is administered by IV infusion for the management of vasodilatory shock. The drug also has been administered by IM+ or subcutaneous+ injection for other uses (e.g., postoperative abdominal distention, diabetes insipidus). Vasopressin also has been applied topically+ to the nasal mucosa (e.g., with a cotton pledget, nasal spray, or dropper) in the treatment of diabetes insipidus.
Vasopressin has been administered by intraosseous (IO)+ injection for advanced cardiovascular life support (ACLS)+, generally when IV access is not readily available; onset of action and systemic concentrations of the drug are comparable to those achieved with venous administration. Vasopressin also has been administered endotracheally+ when vascular (IV or IO) access cannot be established during cardiac arrest; however, IV or IO administration is preferred whenever possible because of more predictable drug delivery and pharmacologic effect. In addition, the drug has been administered by intra-arterial infusion+ in the management of GI hemorrhage+. Intra-arterial infusion of the drug requires specialized techniques, including angiographic placement of the catheter, and should only be performed by clinicians familiar with this method of administration and the management of potential complications.
Vasopressin has been administered by intraosseous (IO)+ injection for advanced cardiovascular life support (ACLS)+, generally when IV access is not readily available; onset of action and systemic concentrations of the drug are comparable to those achieved with venous administration. Vasopressin also has been administered endotracheally+ when vascular (IV or IO) access cannot be established during cardiac arrest; however, IV or IO administration is preferred whenever possible because of more predictable drug delivery and pharmacologic effect. In addition, the drug has been administered by intra-arterial infusion+ in the management of GI hemorrhage+. Intra-arterial infusion of the drug requires specialized techniques, including angiographic placement of the catheter, and should only be performed by clinicians familiar with this method of administration and the management of potential complications.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for VASOPRESSIN-0.9% NACL (vasopressin in 0.9 % sodium chloride):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for VASOPRESSIN-0.9% NACL (vasopressin in 0.9 % sodium chloride):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 1 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Uremia |
There are 2 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Coronary artery disease |
| Hypertension |
There are 4 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Asthma |
| Heart failure |
| Migraine |
| Seizure disorder |
The following adverse reaction information is available for VASOPRESSIN-0.9% NACL (vasopressin in 0.9 % sodium chloride):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 14 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Hyponatremia Low cardiac output Myocardial ischemia Tachyarrhythmia |
None. |
| Rare/Very Rare |
|---|
|
Atrial fibrillation Bradycardia Diabetes insipidus Distal limb ischemia Gastrointestinal vascular ischemia Hemorrhage Hyperbilirubinemia Kidney disease with reduction in glomerular filtration rate (GFr) Peripheral ischemia Thrombocytopenic disorder |
There are 0 less severe adverse reactions.
The following precautions are available for VASOPRESSIN-0.9% NACL (vasopressin in 0.9 % sodium chloride):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
There are no adequate or well-controlled studies of vasopressin in pregnant women, and animal reproduction studies with the drug have not been conducted. It is not known whether vasopressin can cause fetal harm when administered to pregnant women or can affect reproduction capacity; the drug should be used during pregnancy only if the potential benefits justify the potential risks to a fetus. Vasopressin may produce tonic uterine contractions that could threaten the continuation of pregnancy.
Clearance of vasopressin is increased in the second and third trimester of pregnancy; dosages exceeding 0.1 units/minute may be required in patients with postcardiotomy shock and dosages exceeding 0.07 units/minute may be required in patients with septic shock.
Clearance of vasopressin is increased in the second and third trimester of pregnancy; dosages exceeding 0.1 units/minute may be required in patients with postcardiotomy shock and dosages exceeding 0.07 units/minute may be required in patients with septic shock.
It is not known whether vasopressin is distributed into human milk. Some manufacturers recommend that the drug be used with caution in nursing women. Oral absorption of vasopressin in a nursing infant is considered unlikely since the drug is rapidly destroyed in the GI tract.
Consideration may be given to advising a lactating woman to pump and discard her breast milk for 1.5 hours after receiving vasopressin to minimize potential exposure to the infant.
Consideration may be given to advising a lactating woman to pump and discard her breast milk for 1.5 hours after receiving vasopressin to minimize potential exposure to the infant.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for VASOPRESSIN-0.9% NACL (vasopressin in 0.9 % sodium chloride):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for VASOPRESSIN-0.9% NACL (vasopressin in 0.9 % sodium chloride)'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool